SRP415835 Track Settings
 
Comprehensive sequence-based DNA methylation analysis suggests that PanIN lesions are acinar-derived and epigenetically primed for carcinogenesis [Acini, Ducts, PDAC Lesion, PanIN Lesion]   (Human methylome studies)

This track is part of a parent called 'Human methylome studies'. To show other tracks of this parent, go to the Human methylome studies configuration page.

Maximum display mode:       Reset to defaults   

Select views (help):
CpG reads ▾       CpG methylation ▾       AMR       PMD       HMR      
Select subtracks by views and experiment:
 All views CpG reads  CpG methylation  AMR  PMD  HMR 
experiment
SRX18928741 
SRX18928742 
SRX18928743 
SRX18928744 
SRX18928745 
SRX18928746 
SRX18928747 
SRX18928748 
SRX18928749 
SRX18928750 
SRX18928751 
SRX18928752 
SRX18928753 
SRX18928754 
SRX18928755 
SRX18928756 
SRX18928757 
SRX18928758 
SRX18928759 
SRX18928760 
SRX18928761 
SRX18928762 
SRX18928763 
SRX18928764 
SRX18928765 
SRX18928766 
SRX18928767 
SRX18928768 
SRX18928769 
SRX18928770 
SRX18928771 
SRX18928772 
SRX18928773 
SRX18928774 
SRX18928775 
experiment
 All views CpG reads  CpG methylation  AMR  PMD  HMR 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 SRX18928741  CpG methylation  Acini / SRX18928741 (CpG methylation)   schema 
hide
 SRX18928741  HMR  Acini / SRX18928741 (HMR)   schema 
hide
 SRX18928742  CpG methylation  Acini / SRX18928742 (CpG methylation)   schema 
hide
 SRX18928742  HMR  Acini / SRX18928742 (HMR)   schema 
hide
 SRX18928743  CpG methylation  Acini / SRX18928743 (CpG methylation)   schema 
hide
 SRX18928743  HMR  Acini / SRX18928743 (HMR)   schema 
hide
 SRX18928744  HMR  Acini / SRX18928744 (HMR)   schema 
hide
 SRX18928744  CpG methylation  Acini / SRX18928744 (CpG methylation)   schema 
hide
 SRX18928745  CpG methylation  Acini / SRX18928745 (CpG methylation)   schema 
hide
 SRX18928745  HMR  Acini / SRX18928745 (HMR)   schema 
hide
 SRX18928746  CpG methylation  Ducts / SRX18928746 (CpG methylation)   schema 
hide
 SRX18928746  HMR  Ducts / SRX18928746 (HMR)   schema 
hide
 SRX18928747  CpG methylation  Ducts / SRX18928747 (CpG methylation)   schema 
hide
 SRX18928747  HMR  Ducts / SRX18928747 (HMR)   schema 
hide
 SRX18928748  CpG methylation  Ducts / SRX18928748 (CpG methylation)   schema 
hide
 SRX18928748  HMR  Ducts / SRX18928748 (HMR)   schema 
hide
 SRX18928749  CpG methylation  Ducts / SRX18928749 (CpG methylation)   schema 
hide
 SRX18928749  HMR  Ducts / SRX18928749 (HMR)   schema 
hide
 SRX18928750  CpG methylation  PanIN Lesion / SRX18928750 (CpG methylation)   schema 
hide
 SRX18928750  HMR  PanIN Lesion / SRX18928750 (HMR)   schema 
hide
 SRX18928751  CpG methylation  PanIN Lesion / SRX18928751 (CpG methylation)   schema 
hide
 SRX18928751  HMR  PanIN Lesion / SRX18928751 (HMR)   schema 
hide
 SRX18928752  HMR  PanIN Lesion / SRX18928752 (HMR)   schema 
hide
 SRX18928752  CpG methylation  PanIN Lesion / SRX18928752 (CpG methylation)   schema 
hide
 SRX18928753  CpG methylation  PanIN Lesion / SRX18928753 (CpG methylation)   schema 
hide
 SRX18928753  HMR  PanIN Lesion / SRX18928753 (HMR)   schema 
hide
 SRX18928754  CpG methylation  PanIN Lesion / SRX18928754 (CpG methylation)   schema 
hide
 SRX18928754  HMR  PanIN Lesion / SRX18928754 (HMR)   schema 
hide
 SRX18928755  HMR  PDAC Lesion / SRX18928755 (HMR)   schema 
hide
 SRX18928755  CpG methylation  PDAC Lesion / SRX18928755 (CpG methylation)   schema 
hide
 SRX18928756  CpG methylation  PDAC Lesion / SRX18928756 (CpG methylation)   schema 
hide
 SRX18928756  HMR  PDAC Lesion / SRX18928756 (HMR)   schema 
hide
 SRX18928757  CpG methylation  PDAC Lesion / SRX18928757 (CpG methylation)   schema 
hide
 SRX18928757  HMR  PDAC Lesion / SRX18928757 (HMR)   schema 
hide
 SRX18928758  CpG methylation  PDAC Lesion / SRX18928758 (CpG methylation)   schema 
hide
 SRX18928758  HMR  PDAC Lesion / SRX18928758 (HMR)   schema 
hide
 SRX18928759  CpG methylation  PDAC Lesion / SRX18928759 (CpG methylation)   schema 
hide
 SRX18928760  HMR  PDAC Lesion / SRX18928760 (HMR)   schema 
hide
 SRX18928761  HMR  Acini / SRX18928761 (HMR)   schema 
hide
 SRX18928760  CpG methylation  PDAC Lesion / SRX18928760 (CpG methylation)   schema 
hide
 SRX18928761  CpG methylation  Acini / SRX18928761 (CpG methylation)   schema 
hide
 SRX18928762  HMR  Acini / SRX18928762 (HMR)   schema 
hide
 SRX18928762  CpG methylation  Acini / SRX18928762 (CpG methylation)   schema 
hide
 SRX18928763  HMR  Acini / SRX18928763 (HMR)   schema 
hide
 SRX18928764  HMR  Ducts / SRX18928764 (HMR)   schema 
hide
 SRX18928763  CpG methylation  Acini / SRX18928763 (CpG methylation)   schema 
hide
 SRX18928764  CpG methylation  Ducts / SRX18928764 (CpG methylation)   schema 
hide
 SRX18928765  HMR  Ducts / SRX18928765 (HMR)   schema 
hide
 SRX18928765  CpG methylation  Ducts / SRX18928765 (CpG methylation)   schema 
hide
 SRX18928766  HMR  Ducts / SRX18928766 (HMR)   schema 
hide
 SRX18928766  CpG methylation  Ducts / SRX18928766 (CpG methylation)   schema 
hide
 SRX18928767  HMR  PanIN Lesion / SRX18928767 (HMR)   schema 
hide
 SRX18928767  CpG methylation  PanIN Lesion / SRX18928767 (CpG methylation)   schema 
hide
 SRX18928768  HMR  PanIN Lesion / SRX18928768 (HMR)   schema 
hide
 SRX18928768  CpG methylation  PanIN Lesion / SRX18928768 (CpG methylation)   schema 
hide
 SRX18928769  HMR  PanIN Lesion / SRX18928769 (HMR)   schema 
hide
 SRX18928769  CpG methylation  PanIN Lesion / SRX18928769 (CpG methylation)   schema 
hide
 SRX18928770  HMR  PanIN Lesion / SRX18928770 (HMR)   schema 
hide
 SRX18928770  CpG methylation  PanIN Lesion / SRX18928770 (CpG methylation)   schema 
hide
 SRX18928771  HMR  PanIN Lesion / SRX18928771 (HMR)   schema 
hide
 SRX18928772  HMR  PanIN Lesion / SRX18928772 (HMR)   schema 
hide
 SRX18928771  CpG methylation  PanIN Lesion / SRX18928771 (CpG methylation)   schema 
hide
 SRX18928772  CpG methylation  PanIN Lesion / SRX18928772 (CpG methylation)   schema 
hide
 SRX18928773  HMR  PanIN Lesion / SRX18928773 (HMR)   schema 
hide
 SRX18928773  CpG methylation  PanIN Lesion / SRX18928773 (CpG methylation)   schema 
hide
 SRX18928774  HMR  PanIN Lesion / SRX18928774 (HMR)   schema 
hide
 SRX18928775  HMR  PanIN Lesion / SRX18928775 (HMR)   schema 
hide
 SRX18928774  CpG methylation  PanIN Lesion / SRX18928774 (CpG methylation)   schema 
hide
 SRX18928775  CpG methylation  PanIN Lesion / SRX18928775 (CpG methylation)   schema 
    

Study title: Comprehensive sequence-based DNA methylation analysis suggests that PanIN lesions are acinar-derived and epigenetically primed for carcinogenesis
SRA: SRP415835
GEO: not found
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Title
SRX18928741 Acini 0.695 13.3 48809 1350.4 1788 970.5 2901 256340.6 0.992 GSM6915617: Acinar_BF1; Homo sapiens; Bisulfite-Seq
SRX18928742 Acini 0.691 13.8 52373 1317.4 1336 978.2 4993 57597.1 0.993 GSM6915618: Acinar_BF2; Homo sapiens; Bisulfite-Seq
SRX18928743 Acini 0.680 10.0 45574 1341.3 342 998.7 4566 36050.1 0.994 GSM6915619: Acinar_BF3; Homo sapiens; Bisulfite-Seq
SRX18928744 Acini 0.707 12.8 47528 1219.8 1807 955.0 2865 20047.4 0.993 GSM6915620: Acinar_BM1; Homo sapiens; Bisulfite-Seq
SRX18928745 Acini 0.688 12.0 49269 1461.5 1643 959.6 2861 259775.2 0.991 GSM6915621: Acinar_BM3; Homo sapiens; Bisulfite-Seq
SRX18928746 Ducts 0.753 8.2 57282 1225.8 179 918.8 3096 11988.4 0.992 GSM6915622: Duct_B1; Homo sapiens; Bisulfite-Seq
SRX18928747 Ducts 0.777 8.1 57816 1108.9 101 1042.5 1903 23804.6 0.993 GSM6915623: Duct_B2; Homo sapiens; Bisulfite-Seq
SRX18928748 Ducts 0.734 9.8 63725 1033.2 491 1000.6 3677 16632.7 0.994 GSM6915624: Duct_B3; Homo sapiens; Bisulfite-Seq
SRX18928749 Ducts 0.756 8.0 56718 1130.6 444 975.8 2084 30288.7 0.995 GSM6915625: Duct_B4; Homo sapiens; Bisulfite-Seq
SRX18928750 PanIN Lesion 0.713 12.7 58616 1308.4 1402 955.9 4416 35706.8 0.993 GSM6915626: PanIN_BF1; Homo sapiens; Bisulfite-Seq
SRX18928751 PanIN Lesion 0.693 13.1 66366 1448.0 1020 1095.1 3840 28803.2 0.993 GSM6915627: PanIN_BF2; Homo sapiens; Bisulfite-Seq
SRX18928752 PanIN Lesion 0.724 7.7 61460 1236.8 298 1080.7 1343 18445.0 0.995 GSM6915628: PanIN_BF3; Homo sapiens; Bisulfite-Seq
SRX18928753 PanIN Lesion 0.718 12.6 69912 1193.2 698 901.5 2711 14770.8 0.994 GSM6915629: PanIN_BM1; Homo sapiens; Bisulfite-Seq
SRX18928754 PanIN Lesion 0.690 11.4 67361 2197.5 604 903.8 2913 231496.3 0.992 GSM6915630: PanIN_BM3; Homo sapiens; Bisulfite-Seq
SRX18928755 PDAC Lesion 0.702 6.9 50892 1396.7 876 916.8 1519 33658.3 0.995 GSM6915631: PDAC_BF1; Homo sapiens; Bisulfite-Seq
SRX18928756 PDAC Lesion 0.658 17.5 86543 1504.3 1443 1191.0 2189 23217.8 0.995 GSM6915632: PDAC_BF2; Homo sapiens; Bisulfite-Seq
SRX18928757 PDAC Lesion 0.669 12.9 73022 3112.2 852 1041.7 2574 286927.8 0.995 GSM6915633: PDAC_BF3; Homo sapiens; Bisulfite-Seq
SRX18928758 PDAC Lesion 0.687 12.7 61376 1986.5 3061 1285.0 1687 646171.1 0.995 GSM6915634: PDAC_BM1; Homo sapiens; Bisulfite-Seq
SRX18928759 PDAC Lesion 0.628 10.0 69426 4474.5 542 1010.7 2112 364088.8 0.995 GSM6915635: PDAC_BM2; Homo sapiens; Bisulfite-Seq
SRX18928760 PDAC Lesion 0.686 14.0 68509 1417.9 4874 1000.8 2883 13996.7 0.995 GSM6915636: PDAC_BM3; Homo sapiens; Bisulfite-Seq
SRX18928761 Acini 0.722 11.7 49911 1352.1 777 996.6 3695 197195.3 0.990 GSM6915637: Acinar_A0; Homo sapiens; Bisulfite-Seq
SRX18928762 Acini 0.716 13.8 55726 1970.3 1455 991.0 2126 471199.7 0.990 GSM6915638: Acinar_A1; Homo sapiens; Bisulfite-Seq
SRX18928763 Acini 0.716 12.4 56422 2312.2 863 980.5 2120 465415.5 0.992 GSM6915639: Acinar_A2; Homo sapiens; Bisulfite-Seq
SRX18928764 Ducts 0.808 12.5 65661 1122.3 586 1050.5 3613 17566.6 0.990 GSM6915640: Duct_A0; Homo sapiens; Bisulfite-Seq
SRX18928765 Ducts 0.813 16.2 70034 1111.8 1048 985.2 3858 16084.7 0.991 GSM6915641: Duct_A1; Homo sapiens; Bisulfite-Seq
SRX18928766 Ducts 0.817 13.6 69521 1102.1 695 1018.6 3924 15375.4 0.991 GSM6915642: Duct_A2; Homo sapiens; Bisulfite-Seq
SRX18928767 PanIN Lesion 0.736 5.3 45021 1814.7 128 1005.5 1479 593209.8 0.991 GSM6915643: PanIN_A1-1; Homo sapiens; Bisulfite-Seq
SRX18928768 PanIN Lesion 0.699 8.8 56705 2325.8 608 1030.5 1351 693025.1 0.990 GSM6915644: PanIN_A1-2; Homo sapiens; Bisulfite-Seq
SRX18928769 PanIN Lesion 0.750 12.3 64301 1363.8 1381 1055.4 3120 20576.0 0.991 GSM6915645: PanIN_A1-3; Homo sapiens; Bisulfite-Seq
SRX18928770 PanIN Lesion 0.709 12.6 67090 2047.0 885 1078.5 2157 398368.6 0.991 GSM6915646: PanIN_A2a-1; Homo sapiens; Bisulfite-Seq
SRX18928771 PanIN Lesion 0.743 14.3 72880 1465.5 1454 1052.5 5430 58007.3 0.992 GSM6915647: PanIN_A2a-2; Homo sapiens; Bisulfite-Seq
SRX18928772 PanIN Lesion 0.755 11.9 70179 1316.7 1246 1042.2 3604 25450.8 0.991 GSM6915648: PanIN_A2a-3; Homo sapiens; Bisulfite-Seq
SRX18928773 PanIN Lesion 0.736 9.5 62825 1658.6 941 1043.6 4581 76629.4 0.991 GSM6915649: PanIN_A2b-1; Homo sapiens; Bisulfite-Seq
SRX18928774 PanIN Lesion 0.725 12.9 69005 2062.8 1203 1054.8 2312 327002.3 0.991 GSM6915650: PanIN_A2b-2; Homo sapiens; Bisulfite-Seq
SRX18928775 PanIN Lesion 0.747 13.0 70438 1388.7 1254 1047.3 3180 30257.8 0.991 GSM6915651: PanIN_A2b-3; Homo sapiens; Bisulfite-Seq

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.